OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences. Data from the Phase IV study carried out in Europe has been selected for a poster session and special oral presentation at the 5th European Conference on Head and Neck Oncology. In addition, data from the Phase III study carried out in the United States has been selected for a poster presentation at the 8th International Head and Neck Cancer Conference.
OncoSec's most advanced stage treatment platform, OMS ElectroChemotherapy, is a targeted ablation therapy, which utilizes the OMS to locally deliver bleomcyin to the tumor. This treatment platform preferentially kills targeted cancer cells while sparing surrounding normal healthy tissue. OMS ElectroChemotherapy has been developed up to Phase III clinical trials in the United States for the treatment of recurrent head and neck cancer and in Phase I/II for the treatment of recurrent breast cancer. In addition, Phase IV pre-marketing studies to support the commercialization of the OMS system in Europe were also performed for the treatment of primary and recurrent head and neck cancers and cutaneous skin cancers.
"Since acquiring the OMS ElectroChemotherapy assets in March 2011, we have been working diligently to compile and analyze data from the Phase III and IV studies carried out in the United States and Europe. We are excited that we will now have the opportunity to share this data with the public in the coming months," said Punit Dhillon, President and CEO. "With this data, we expect to finalize our clinical development plan and move forward with commercializing the OMS ElectroChemotherapy platform with a partner, either regionally or globally."
The Phase IV head and neck cancer results, carried out in Europe, will be presented at:
The 5th European Conference on Head and Neck Oncology
April 18-21, 2012
Special Poster Session and Presentation
"Interim analysis of an open labeled, single arm multicenter study of electrochemotherapy in recurrent head and neck cancer"
The 8th International Head and Neck Cancer Conference
Toronto Convention Center
July 21-25, 2012
"Interim analysis of two randomized Phase 3 trials comparing electrochemotherapy to surgery in recurrent head and neck cancer"